Stocks Health care RNAC
NASDAQ · Health careCartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. brought in $1.5M of revenue over the twelve months to June 30, 2026, up 44.0% from a year earlier. It posted a net loss of $151.9M. In fiscal 2025 capital spending exceeded operating cash flow by $79.4M. At June 30, 2026 it held $147.6M in cash against $52.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Cartesian Therapeutics, Inc. does
Cartesian Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNAC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.8M | -$130.3M | -$5.02 | -$79.4M |
| 2024 | $38.9M | -$77.4M | -$4.49 | -$32.8M |
| 2023 | $26M | -$219.7M | -$49.76 | -$51.4M |
| 2022 | $110.8M | $35.4M | $3.00 | -$32.8M |
| 2021 | $85.1M | -$25.7M | -$6.59 | -$61.5M |
| 2020 | $16.6M | -$68.9M | -$20.38 | $34.1M |
Latest SEC filings
What Cartesian Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 22, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026
- June 9, 2026
- May 26, 2026
- May 6, 2026Passive stake changed SCHEDULE 13G/A
- April 30, 2026
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about RNAC
What does Cartesian Therapeutics, Inc. do?
Cartesian Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RNAC.
Is Cartesian Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $151.9M on revenue of $1.5M.
How much revenue does Cartesian Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Cartesian Therapeutics, Inc. reported revenue of $1.5M. That is 44.0% more than a year earlier.
When did Cartesian Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 13, 2026.
Similar companies
Follow RNAC
Get an email when Cartesian Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RNAC: get an email when it filesWhere the numbers come from
Financial figures are the values Cartesian Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.